| Recruiting | Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions Overall Response Rate | Phase 2 | 2025-07-01 |
| Active Not Recruiting | Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer EFS, pCR Rate | Phase 2 | 2025-07-01 |
| Recruiting | Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification EGFR Positive Non-small Cell Lung Cancer, MET Amplification | Phase 2 | 2025-01-01 |
| Recruiting | Nutrition Impact on Immunotherapy of Cancer Nutrition Disorders, Immunotherapy, Cancer | Phase 3 | 2024-06-01 |
| Recruiting | Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cance Small-cell Lung Cancer, Residual Tumor, Radiation | — | 2024-04-17 |
| Recruiting | Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | 2023-09-20 |
| Completed | Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial I Myocardial Infarction, Diabete Type 2, Glucose Intolerance | Phase 4 | 2023-05-08 |
| Not Yet Recruiting | Colchicine Use for Primary Prevention of Coronary Artery Disease Coronary Artery Disease | Phase 3 | 2022-12-06 |
| Unknown | Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large Overall Survival | Phase 2 | 2022-05-01 |
| Unknown | Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC PFS, OS | Phase 2 | 2022-02-01 |
| Unknown | Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer Overall Survival | Phase 2 | 2022-01-01 |
| Unknown | Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction Myocardial Infarction, Hypertension | Phase 4 | 2021-10-01 |
| Recruiting | Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma Carcinoma, Adenoid Cystic | Phase 2 | 2021-07-01 |
| Unknown | Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Inserti Carcinoma, Non-Small-Cell Lung | Phase 2 | 2021-07-01 |
| Unknown | Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719 PFS | Phase 2 | 2021-02-01 |
| Unknown | Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR Carcinoma, Non-Small-Cell Lung | Phase 3 | 2021-01-01 |
| Unknown | CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation Lymphoma, B-Cell, Leukemia, B-Cell, Minimal Disease, Residual | N/A | 2018-07-15 |
| Completed | Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer Overall Survival | Phase 2 | 2018-01-26 |
| Completed | Maintenance Therapy for Small-cell Lung Cancer Progression Free Survival | Phase 2 | 2017-01-01 |
| Completed | Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Canc EGFR-TKI Resistant Mutation | — | 2015-10-01 |
| Completed | Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer Progression Free Survival | Phase 2 / Phase 3 | 2015-08-01 |
| Unknown | Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab Pulmonary Fibrosis | Phase 2 | 2013-08-01 |
| Completed | Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | — | 2013-08-01 |
| Completed | Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma Liver Cancer | Phase 2 / Phase 3 | 2013-08-01 |